Prediction of non-linear pharmacokinetics in humans of an antibody-drug conjugate (ADC) when evaluation of higher doses in animals is limited by tolerability: Case study with an anti-CD33 ADC

For antibody-drug conjugates (ADCs) that carry a cytotoxic drug, doses that can be administered in preclinical studies are typically limited by tolerability, leading to a narrow dose range that can be tested. For molecules with non-linear pharmacokinetics (PK), this limited dose range may be insuffi...

Descripción completa

Detalles Bibliográficos
Autores principales: Figueroa, Isabel, Leipold, Doug, Leong, Steve, Zheng, Bing, Triguero-Carrasco, Montserrat, Fourie-O'Donohue, Aimee, Kozak, Katherine R., Xu, Keyang, Schutten, Melissa, Wang, Hong, Polson, Andrew G., Kamath, Amrita V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150628/
https://www.ncbi.nlm.nih.gov/pubmed/29757698
http://dx.doi.org/10.1080/19420862.2018.1465160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150628/
https://www.ncbi.nlm.nih.gov/pubmed/29757698
http://dx.doi.org/10.1080/19420862.2018.1465160

Ejemplares similares